phosphatidylinositol

Zandelisib is an inhibitor of phosphatidylinositol 3-kinase (PI3K)(p110δ, IC50 of 3.5 nM), and with antineoplastic activity.

BF738735 is a selective inhibitor of phosphatidylinositol 4-kinase III beta (PI4KIIIβ, IC50 = 5.7 nM) showing higher activity over α(IC50 = 1.7 μM). BF738735 exhibits a broad spectrum of antiviral activity.

PI-273, a Substrate-Competitive, Specific Small-Molecule Inhibitor of PI4KIIα, Inhibits the Growth of Breast Cancer Cells

PI4KIIIbeta-IN-10 is a potent inhibitor of PI4KIIIβ with an IC50 value of 3.6 nM.

PI4KIIIbeta-IN-9 is a potent inhibitor of PI4KIIIβ [IC50 of 7 nM].

MMV390048 is an antimalarial agent and is a representative of a new chemical class of Plasmodium PI4K inhibitor (Kdapp=0.3 μM). MMV390048 binds to the ATP binding site of Plasmodium PI4K and does not bind to other P. falciparum and human kinases apart from human PIP4K2C, thus alleviating potential kinase-mediated safety concerns.

T-00127_HEV1 is an inhibitor of phosphatidylinositol 4-kinase III beta (IC50: 60 nM).

PI3-Kinase inhibitor targets PI3Kγ with an IC50 of 1.5 nM and shows selectivity over PI3Kα, PI3Kβ, and PI3Kδ, exhibiting IC50 values of 3,333 nM, >10,000 nM, and >1,000 nM, respectively. At 100 mg/kg, it reduces tumor growth in a 4T1 murine mammary cancer model. In a mouse model of experimental autoimmune encephalomyelitis (EAE), it lessens disease severity when administered at doses of 20 or 80 mg/kg.

PIK-93, the first potent synthetic PI4K inhibitor, exhibits an IC50 of 19 nM and also inhibits PI3Kα with an IC50 of 39 nM.

GSK-A1 is a specific inhibitor of PI4KA, also inhibited calcium-driven PRL secretion without affecting calcium signaling and Prl expression. GSK-A1 has anti-hepatitis C virus (HCV) potential.

Psoralidin inhibits Akt phosphorylation and phosphatidylinositol 3-kinase activation and transcriptionally. Psoralidin possesses anticancer and chemopreventive properties.

LY-294002 hydrochloride (NSC 697286) is a synthetic molecule inhibitor of PI3Kα/δ/β (IC50: 0.5/0.57/0.97 μM, in cell-free assays); more stable than Wortmannin in solution, and also is a blocker of autophagosome formation.

BQR-695 (NVP-BQR695) is a phosphatidylinositol 4-kinase (PI4K) inhibitor with IC50s of 80 and 3.5 nM for human PI4KIIIβ and Plasmodium variant of PI4KIIIβ, respectively.

KDU691 is a PI4K inhibitor.

UCB9608 is a selective and orally active PI4KIIIβ inhibitor (IC50: 11 nM), selective over PI3KC2 α, β, and γ lipid kinases.

Phosphatidylinositol 4,5-bisphosphate (L-alpha-Phosphatidylinositol-4,5-bisphosphate), a critical phospholipid in cell membranes, serves as a substrate for both phospholipase C (PLC) and phosphoinositide 3-kinase (PI3K) and acts as a primary messenger [1] [2] [3].

L-α-Phosphatidylinositol (liver, bovine) (sodium) is a reagent used in biochemical reactions.

Phosphatidylinositolphosphodiesterase hydrolyzes phosphatidylinositol to produce a mixture of diacylglycerol and inositol 1- and 1,2-cyclic phosphate esters.

L-α-Phosphatidylinositol-4,5-bisphosphate ammonium is a reagent used in biochemical reactions.

Phosphatidylinositols, comprising about 10% of total cellular phospholipids, are glycerophospholipids featuring a glycerol backbone, two non-polar fatty acid tails (primarily C16:0 and C18:0), and a polar inositol head group. Synthesized from cytidine diphosphate diacylglycerol (CPD-DAG) and myoinositol via phosphoinositol synthase, these compounds play pivotal roles in cellular processes, including calcium regulation, vesicle trafficking, mitogenesis, cell survival, and actin rearrangement. Phosphorylation of their inositol rings produces phosphoinositides, crucial for these cellular functions. [Matreya, LLC. Catalog No. 1048]

Phosphatidylinositols sodium are a type of lipid present in organisms that has an enrichment effect and is involved in regulating various cell functions. They can be used in the functional study of lipid membranes.

L-α-lysophosphatidylinositol sodium is an endogenous ligand of GPR55 and an endogenous cannabinoid neurotransmitter that is involved in controlling cell survival and tumor progression.

WAY-299017 is a potent and selective UPPS inhibitor for the treatment of bacterial infections.

CID 16020046 (C390-0219) is a selective GPR55 antagonist, inhibiting GPR55 constitutive activity with IC50 of 0.15 μM in yeast.